JP2019537449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537449A5 JP2019537449A5 JP2019527171A JP2019527171A JP2019537449A5 JP 2019537449 A5 JP2019537449 A5 JP 2019537449A5 JP 2019527171 A JP2019527171 A JP 2019527171A JP 2019527171 A JP2019527171 A JP 2019527171A JP 2019537449 A5 JP2019537449 A5 JP 2019537449A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- abp
- cdr
- sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims 195
- 108091000831 antigen binding proteins Proteins 0.000 claims 195
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 76
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 67
- 239000000427 antigen Substances 0.000 claims 46
- 102000036639 antigens Human genes 0.000 claims 46
- 108091007433 antigens Proteins 0.000 claims 46
- 239000003814 drug Substances 0.000 claims 38
- 210000004027 cell Anatomy 0.000 claims 36
- 239000002773 nucleotide Substances 0.000 claims 34
- 125000003729 nucleotide group Chemical group 0.000 claims 34
- 239000002157 polynucleotide Substances 0.000 claims 32
- 102000040430 polynucleotide Human genes 0.000 claims 32
- 108091033319 polynucleotide Proteins 0.000 claims 32
- 239000012634 fragment Substances 0.000 claims 28
- 239000013604 expression vector Substances 0.000 claims 23
- 230000003308 immunostimulating effect Effects 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 229960001438 immunostimulant agent Drugs 0.000 claims 11
- 239000003022 immunostimulating agent Substances 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 10
- 210000003289 regulatory T cell Anatomy 0.000 claims 10
- 102000047758 human TNFRSF18 Human genes 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 7
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims 6
- 101000912551 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Fimbrin Proteins 0.000 claims 6
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 5
- -1 EGFR inhibitors Substances 0.000 claims 5
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 4
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 4
- 210000002865 immune cell Anatomy 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 101000732629 Drosophila melanogaster Anillin Proteins 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 3
- 239000013059 antihormonal agent Substances 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940121647 egfr inhibitor Drugs 0.000 claims 3
- 239000003966 growth inhibitor Substances 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 230000001629 suppression Effects 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 102100039160 Amiloride-sensitive amine oxidase [copper-containing] Human genes 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 101710167313 Drebrin-like protein Proteins 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101100029157 Homo sapiens PEF1 gene Proteins 0.000 claims 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 102100035845 Peflin Human genes 0.000 claims 2
- 101100000443 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ACC1 gene Proteins 0.000 claims 2
- 101100489940 Schizosaccharomyces pombe (strain 972 / ATCC 24843) abp2 gene Proteins 0.000 claims 2
- 230000006052 T cell proliferation Effects 0.000 claims 2
- 101100489942 Zea mays ABP4 gene Proteins 0.000 claims 2
- 101100489943 Zea mays ABP5 gene Proteins 0.000 claims 2
- 101100108219 Zea mays ADF2 gene Proteins 0.000 claims 2
- 101100108223 Zea mays ADF3 gene Proteins 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 108091008042 inhibitory receptors Proteins 0.000 claims 2
- 244000309459 oncolytic virus Species 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 230000009466 transformation Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100024263 CD160 antigen Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 101150046249 Havcr2 gene Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 1
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102000002698 KIR Receptors Human genes 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 101100425749 Mus musculus Tnfrsf18 gene Proteins 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 102100028749 Neuritin Human genes 0.000 claims 1
- 101710189685 Neuritin Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 101100489939 Prunus persica ABP20 gene Proteins 0.000 claims 1
- 102100029198 SLAM family member 7 Human genes 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000008484 agonism Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 230000030741 antigen processing and presentation Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000005931 immune cell recruitment Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 230000001839 systemic circulation Effects 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662497428P | 2016-11-19 | 2016-11-19 | |
| US62/497,428 | 2016-11-19 | ||
| US201762448644P | 2017-01-20 | 2017-01-20 | |
| US62/448,644 | 2017-01-20 | ||
| PCT/US2017/062443 WO2018094300A1 (en) | 2016-11-19 | 2017-11-19 | Anti-gitr antigen-binding proteins and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019537449A JP2019537449A (ja) | 2019-12-26 |
| JP2019537449A5 true JP2019537449A5 (enExample) | 2021-01-07 |
| JP7572147B2 JP7572147B2 (ja) | 2024-10-23 |
Family
ID=62146165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527171A Active JP7572147B2 (ja) | 2016-11-19 | 2017-11-19 | 抗ｇｉｔｒ抗原結合タンパク質およびその使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10988545B2 (enExample) |
| EP (1) | EP3541845A1 (enExample) |
| JP (1) | JP7572147B2 (enExample) |
| KR (1) | KR102574071B1 (enExample) |
| CN (1) | CN110248960A (enExample) |
| AU (1) | AU2017362721A1 (enExample) |
| BR (1) | BR112019010128A2 (enExample) |
| CO (1) | CO2019006424A2 (enExample) |
| IL (1) | IL266720A (enExample) |
| JO (1) | JOP20190100A1 (enExample) |
| MA (1) | MA46844A (enExample) |
| MX (1) | MX2019005821A (enExample) |
| PH (1) | PH12019501108A1 (enExample) |
| TW (1) | TWI783953B (enExample) |
| UA (1) | UA126389C2 (enExample) |
| WO (1) | WO2018094300A1 (enExample) |
| ZA (1) | ZA201902939B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102239781B1 (ko) * | 2019-04-08 | 2021-04-13 | 주식회사 녹십자 | Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| US10994021B1 (en) * | 2020-04-11 | 2021-05-04 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | Tetravalent antibody-drug conjugates and use thereof |
| CN116113401A (zh) | 2020-06-08 | 2023-05-12 | 华盛顿大学 | 抗体结合的纳米颗粒 |
| KR102475255B1 (ko) * | 2021-05-10 | 2022-12-09 | 메디맵바이오 주식회사 | 항-gitr 항체 및 이의 용도 |
| WO2023094507A1 (en) * | 2021-11-24 | 2023-06-01 | Formycon Ag | Improved ace2 fusion proteins |
| CN118946582A (zh) | 2022-03-15 | 2024-11-12 | 耶达研究及发展有限公司 | 抗糖皮质激素诱导的tnfr相关（gitr）蛋白抗体及其用途 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL97459A0 (en) | 1990-03-09 | 1992-06-21 | Hybritech Inc | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| EP0626012B1 (en) | 1992-02-11 | 2003-07-09 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US5945403A (en) | 1997-05-30 | 1999-08-31 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| US6503184B1 (en) | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| DK1272647T3 (en) | 2000-04-11 | 2014-12-15 | Genentech Inc | Multivalent antibodies and uses thereof |
| EP1189379A1 (en) | 2000-09-14 | 2002-03-20 | Alcatel | Method and system for enhancing channel capacity in a point to multipoint radio communications system |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| DE60144063D1 (de) | 2000-12-18 | 2011-03-31 | Dyax Corp | Gerichtete bibliotheken die genetisch verpackt sind |
| WO2003006058A1 (en) | 2001-07-12 | 2003-01-23 | Wyeth | Cd25+ differential markers and uses thereof |
| CA2455365C (en) | 2001-08-03 | 2014-07-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US6715202B2 (en) | 2001-11-02 | 2004-04-06 | American Standard International Inc. | Tube bender for forming serpentine heat exchangers from spine fin tubing |
| US6579430B2 (en) | 2001-11-02 | 2003-06-17 | Innovative Technology Licensing, Llc | Semiconductor wafer plating cathode assembly |
| US20030215914A1 (en) | 2001-12-10 | 2003-11-20 | Erwin Houtzager | Structure for presenting desired peptide sequences |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| CN1930288B (zh) | 2002-04-09 | 2012-08-08 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| ES2362419T3 (es) | 2002-04-09 | 2011-07-05 | Kyowa Hakko Kirin Co., Ltd. | Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa. |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| RS20050481A (sr) | 2002-12-20 | 2007-08-03 | Biogen Idec Ma Inc., | Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima |
| NZ543654A (en) | 2003-05-23 | 2009-05-31 | Wyeth Corp | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| WO2005007150A2 (en) | 2003-07-17 | 2005-01-27 | Bar-Ilan University | Method for inhibiting protein synthesis in sperm |
| US6864697B1 (en) | 2003-08-06 | 2005-03-08 | Taiwan Semiconductor Manufacturing Co. Ltd | Flip-over alignment station for probe needle adjustment |
| US20050035586A1 (en) | 2003-08-12 | 2005-02-17 | Martin Samuel V. | Magnetically pulse welded underbody |
| JP2005081663A (ja) | 2003-09-08 | 2005-03-31 | Nissan Motor Co Ltd | 樹脂製チューブ及び燃料系配管用チューブ |
| ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| BR122019012028B1 (pt) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
| US20060002932A1 (en) | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
| CN101484182B (zh) | 2005-04-06 | 2014-06-11 | Ibc药品公司 | 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JPWO2007060918A1 (ja) | 2005-11-24 | 2009-05-07 | 大日本住友製薬株式会社 | 新規なメモリーｃｔｌ誘導増強剤 |
| ES2399075T3 (es) | 2006-08-30 | 2013-03-25 | Genentech, Inc. | Anticuerpos multiespecíficos |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| CA2772613C (en) | 2009-09-03 | 2020-03-10 | Schering Corporation | Anti-gitr antibodies |
| ES2535393T3 (es) | 2009-12-22 | 2015-05-11 | F. Hoffmann-La Roche Ag | Agregación dependiente de secuencia |
| WO2012009568A2 (en) | 2010-07-16 | 2012-01-19 | Adimab, Llc | Antibody libraries |
| JP5925893B2 (ja) * | 2011-08-23 | 2016-05-25 | ロシュ グリクアート アーゲー | 二重特異性抗原結合分子 |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| LT2831113T (lt) | 2012-03-28 | 2018-06-25 | Sanofi | Antikūnai prieš bradikinino b1 receptoriaus ligandus |
| CN103217489B (zh) * | 2013-01-15 | 2016-03-09 | 珠海市丽珠单抗生物技术有限公司 | 一种测定蛋白纯化工艺过程中样品的糖基化和末端修饰情况的方法 |
| UY35517A (es) * | 2013-04-04 | 2014-10-31 | Mabxience S A | Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína |
| CN105658672A (zh) * | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
| DK3041949T3 (da) * | 2013-09-05 | 2021-07-26 | Vib Vzw | Celler, der producerer fc-holdige molekyler med modificerede glycosyleringsmønstre, og fremgangsmåder og anvendelser deraf |
| ES2923641T3 (es) | 2013-12-30 | 2022-09-29 | Epimab Biotherapeutics Inc | Inmunoglobulina con Fabs en tándem y usos de la misma |
| SMT202100116T1 (it) * | 2014-05-28 | 2021-05-07 | Agenus Inc | Anticorpi anti-gitr e metodi di utilizzo degli stessi |
| CN110658340B (zh) * | 2015-01-08 | 2023-10-31 | 苏州康宁杰瑞生物科技有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
| EP3383430A4 (en) * | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
-
2017
- 2017-06-16 JO JOP/2019/0100A patent/JOP20190100A1/ar unknown
- 2017-11-19 JP JP2019527171A patent/JP7572147B2/ja active Active
- 2017-11-19 CN CN201780071351.3A patent/CN110248960A/zh active Pending
- 2017-11-19 KR KR1020197017116A patent/KR102574071B1/ko active Active
- 2017-11-19 BR BR112019010128A patent/BR112019010128A2/pt unknown
- 2017-11-19 WO PCT/US2017/062443 patent/WO2018094300A1/en not_active Ceased
- 2017-11-19 UA UAA201906793A patent/UA126389C2/uk unknown
- 2017-11-19 MA MA046844A patent/MA46844A/fr unknown
- 2017-11-19 EP EP17817953.7A patent/EP3541845A1/en active Pending
- 2017-11-19 MX MX2019005821A patent/MX2019005821A/es unknown
- 2017-11-19 AU AU2017362721A patent/AU2017362721A1/en not_active Abandoned
- 2017-11-20 TW TW106140182A patent/TWI783953B/zh not_active IP Right Cessation
-
2018
- 2018-02-20 US US15/900,168 patent/US10988545B2/en active Active
-
2019
- 2019-05-10 ZA ZA2019/02939A patent/ZA201902939B/en unknown
- 2019-05-17 PH PH12019501108A patent/PH12019501108A1/en unknown
- 2019-05-19 IL IL266720A patent/IL266720A/en unknown
- 2019-06-19 CO CONC2019/0006424A patent/CO2019006424A2/es unknown
-
2021
- 2021-03-10 US US17/197,547 patent/US20210269542A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI788327B (zh) | 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途 | |
| JP2020511947A5 (enExample) | ||
| TWI773646B (zh) | 結合lag-3的分子和其使用方法 | |
| CN109641049B (zh) | Cd3结合抗体 | |
| JP2018533371A5 (enExample) | ||
| TWI758267B (zh) | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 | |
| JP2019537449A5 (enExample) | ||
| JP2020530289A5 (enExample) | ||
| JP2019517539A (ja) | 併用療法 | |
| JP2020536543A5 (enExample) | ||
| KR20190089090A (ko) | Pd-l1 항체와 이를 이용한 치료 및 진단 | |
| JP2024530451A (ja) | 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用 | |
| TW202241956A (zh) | 新穎抗cd24抗體 | |
| CN114901306A (zh) | 用于治疗癌症的疗法 | |
| JP2023518400A (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| JP2024138555A (ja) | 抗体製剤 | |
| US20230322953A1 (en) | Binding protein having h2l2 and hcab structures | |
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| JP2024054284A (ja) | ガンの処置のための結合分子 | |
| JP2025510232A (ja) | Ｉｌｔ３及びｃｄ３結合剤及びその使用方法 | |
| JP7486616B2 (ja) | Ｂｔｌａ抗体 | |
| TW202229348A (zh) | 使用sea-cd40治療葡萄膜黑色素瘤 | |
| US20250339519A1 (en) | Combination of cytokine fusion proteins with cd8 antigen binding molecules | |
| WO2025041097A1 (en) | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof | |
| KR20220144821A (ko) | Cd137 결합 분자 및 그것의 용도 |